Get the Stockscreener App
13.75
0.07%
0.010
Organon Co stock is traded at $13.75, with a volume of 1.77M.
It is up +0.07% in the last 24 hours and up +1.78% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.74
Open:
$13.74
24h Volume:
1.77M
Relative Volume:
0.68
Market Cap:
$3.61B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.65
EPS:
0.9387
Net Cash Flow:
$708.00M
1W Performance:
+0.22%
1M Performance:
+1.78%
6M Performance:
+69.75%
1Y Performance:
+48.17%
1-Day Range:
$13.73
$13.76
1-Week Range:
$13.66
$13.76
52-Week Range:
$5.69
$13.76
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.75 | 3.61B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,255.40 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.24 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.96 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.55 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.86 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com
Organon & Co. (NYSE:OGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Orographic Financial Advisors, LLC's Organon & Co(OGN) Holding History - GuruFocus
how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com - Investing.com South Africa
Organon (OGN): Pentwater Capital discloses 18.1M-share, 6.9% ownership stake - Stock Titan
Kevin Hern sells stocks in Organon & Co. and Versant Media Group - Investing.com Nigeria
Kevin Hern sells stocks in Organon & Co. and Versant Media Group By Investing.com - Investing.com Australia
This House of Representative Just Sold Up To $30K In Organon Stock - Benzinga
Organon & Co To Go Ex-Dividend On August 14th, 2026 With 0.02 USD Dividend Per Share - 富途牛牛
Organon & Co. (NYSE:OGN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN - MarketBeat
Quantinno Capital Management LP Sells 98,466 Shares of Organon & Co. $OGN - MarketBeat
Organon & Co. R&D Chief Juan Camilo Arjona Ferreira Completes Final RSU Vesting and Tax Withholding - Kalkine Media
Organon & Co. (OGN) CMO exercises 11,519 RSUs and withholds 4,134 shares for costs - Stock Titan
Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System - MarketBeat
Rep. Kevin Hern Sells Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Trading the Move, Not the Narrative: (OGN) Edition - Stock Traders Daily
Organon opens enrollment for Miudella IUD safety program By Investing.com - Investing.com Australia
Organon opens enrollment for Miudella IUD safety program - Investing.com
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability - Business Wire
Organon earnings in focus as Sun Pharma deal looms By Investing.com - Investing.com UK
Organon earnings in focus as Sun Pharma deal looms - Investing.com
Organon & Co stock hits 52-week high at 13.61 USD - Investing.com Australia
Organon & Co. (NYSE:OGN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
OGN (NYSE: OGN) details 14,761-share Rule 144 common stock sale plan - Stock Titan
Organon & Co. (OGN) Stock Analysis: Valuation Insights and Investor Outlook Amidst Market Challenges - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Weekly Recap: Moody's upgrade prospect after Sun Pharmaceutical and Q2 EPS $0.85 - TradingView
Organon Co earnings missed by $0.50, revenue fell short of estimates - Investing.com
Organon & Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Organon declares $0.02 quarterly dividend per share By Investing.com - Investing.com Nigeria
Organon: Q2 Earnings Snapshot - WKYC
Press Release: Organon Announces Quarterly Dividend - Moomoo
Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend - MarketBeat
First Trust Advisors LP Has $19.33 Million Position in Organon & Co. $OGN - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
OGN|Organon & Co|Price:13.535|Chg%:+0.015 - TradingKey
Organon & Co. (OGN) to Announce Quarterly Earnings on Tuesday - MarketBeat
India healthcare M&A hits record value as pharma takes centre stage - DealStreetAsia
OGN Looks 6.8% Undervalued on GF Value™ - GuruFocus
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):